These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32051271)

  • 1. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
    Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.
    Martinez O; Tantral L; Mulherkar N; Chandran K; Basler CF
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S825-32. PubMed ID: 21987758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model.
    Lee HN; McWilliams IL; Lewkowicz AP; Engel K; Ireland DDC; Kelley-Baker L; Thacker S; Piccardo P; Manangeeswaran M; Verthelyi D
    Emerg Microbes Infect; 2021 Dec; 10(1):2076-2089. PubMed ID: 34674613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
    Locher S; Schweneker M; Hausmann J; Zimmer G
    J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
    Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
    J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 8. Ebola virus-induced eye sequelae: a murine model for evaluating glycoprotein-targeting therapeutics.
    Lee HN; Xu B; Lewkowicz AP; Engel K; Kelley-Baker L; McWilliams IL; Ireland DDC; Kielczewski JL; Li J; Fariss RN; Campos MM; Baum A; Kyratsous C; Pascal K; Chan CC; Caspi RR; Manangeeswaran M; Verthelyi D
    EBioMedicine; 2024 Jun; 104():105170. PubMed ID: 38823088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.
    Brunton B; Rogers K; Phillips EK; Brouillette RB; Bouls R; Butler NS; Maury W
    PLoS Negl Trop Dis; 2019 Jun; 13(6):e0006983. PubMed ID: 31242184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory.
    Yang W; Li W; Zhou W; Wang S; Wang W; Wang Z; Feng N; Wang T; Xie Y; Zhao Y; Yan F; Xia X
    Virol Sin; 2024 Jun; 39(3):434-446. PubMed ID: 38556051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced
    Chabot S; Gimie Y; Obeid K; Kim J; Meseda CA; Konduru K; Kaplan G; Sheng Fowler L; Weir JP; Peden K; Major ME
    J Virol; 2022 Sep; 96(18):e0116621. PubMed ID: 36069549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.
    Konduru K; Shurtleff AC; Bavari S; Kaplan G
    J Virol Methods; 2018 Apr; 254():1-7. PubMed ID: 29355585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.
    González-Hernández M; Hoffmann M; Brinkmann C; Nehls J; Winkler M; Schindler M; Pöhlmann S
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein disulfide isomerases (PDIs) negatively regulate ebolavirus structural glycoprotein expression in the endoplasmic reticulum (ER) via the autophagy-lysosomal pathway.
    Wang B; Zhang J; Liu X; Chai Q; Lu X; Yao X; Yang Z; Sun L; Johnson SF; Schwartz RC; Zheng YH
    Autophagy; 2022 Oct; 18(10):2350-2367. PubMed ID: 35130104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
    van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
    Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
    J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1.
    Ao Z; Wang L; Azizi H; Olukitibi TA; Kobinger G; Yao X
    J Virol; 2021 Jul; 95(15):e0236820. PubMed ID: 34011553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.